Analysis of Global Research Trends in Immunoconjugates for Cervical Cancer: A Bibliometric and Thematic Mapping Study from 2015 to 2024

1

Immunoconjugates, especially antibody-drug conjugates, are becoming significant treatment options for recurrent or metastatic cervical cancer.
2

Research output on immunoconjugates has surged since 2021, reflecting a shift towards clinical applications and safety optimization.
3

Tisotumab vedotin, the first FDA-approved immunoconjugate for cervical cancer, shows promising efficacy but requires careful monitoring for ocular toxicity.
4

Emerging therapies like sacituzumab govitecan and trastuzumab deruxtecan demonstrate potential in treating recurrent cervical cancer with notable response rates.
5

The study highlights the need for biomarker-guided approaches and combination strategies to address challenges like resistance and adverse effects.

Frontiers In Oncology

by Xiaodong Wang, Di Xiong, Songli Cui, Bingchen Duan, Gouping Ding, Yiping Huang, Qianqian Wang
April 23, 2026

1